BEUDAMED
    FDA Adverse Event Injury Summary report: N

    NEUWAVE PR PROBE 15CM 17GA

    MDR report key: 12142583 · Received July 9, 2021

    Report

    Report Number
    3008769756-2021-00067
    Event Type
    Injury
    Date Received
    July 9, 2021
    Date of Event
    March 7, 2019
    Report Date
    June 9, 2021
    Manufacturer
    NEUWAVE MEDICAL, INC.
    Product Code
    NEY
    UDI-DI
    00853719006395
    PMA / PMN Number
    K160936
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    CA, US
    Reporter Occupation
    OTHER

    Narratives

    Additional Manufacturer Narrative · 1

    (B)(4). BATCH #: UNK. AS THE DEVICE WAS NOT RETURNED, AN ANALYSIS INVESTIGATION COULD NOT BE PERFORMED. A CONCLUSION COULD NOT BE REACHED AS TO WHAT MAY HAVE CAUSED OR CONTRIBUTED TO THE EVENT. WE DID NOT RECEIVE A BATCH OR LOT NUMBER FOR THE PRODUCT INVOLVED IN THIS COMPLAINT. THEREFORE, WE WERE UNABLE TO CHECK MANUFACTURING RECORDS FOR ANY RELATED NON-CONFORMANCE. ATTEMPTS ARE BEING MADE TO OBTAIN THE FOLLOWING INFORMATION. TO DATE NO RESPONSE HAS BEEN PROVIDED. IF FURTHER DETAILS ARE RECEIVED AT A LATER DATE, A SUPPLEMENTAL MEDWATCH WILL BE SENT. DOES THE AUTHOR/SURGEON BELIEVE THAT THE NEUWAVE DEVICES MENTIONED IN THIS ARTICLE CAUSED/CONTRIBUTED TO THE REPORTED EVENTS IN THE ARTICLE?

    Description of Event or Problem · 1

    IT WAS REPORTED VIA JOURNAL ARTICLE TITLE: THE EFFECT OF TUMOR SIZE AND LOCATION ON EFFICACY AND SAFETY OF USAND CT- GUIDED PERCUTANEOUS MICROWAVE ABLATION IN RENAL CELL CARCINOMAS. AUTHORS: SEPIDEH SHAKERI1 · SOHRAB AFSHARI MIRAK1 · AMIRHOSSEIN MOHAMMADIAN BAJGIRAN1 · ALLAN PANTUCK2 · ANTHONY SISK3 · PREETI AHUJA1 · DAVID S. LU1 · STEVEN S. RAMAN1, CITATION: ABDOMINAL RADIOLOGY (2019) 44:2308¿2315 HTTPS://DOI.ORG/10.1007/S00261-019-01967-8 THIS STUDY COHORT AIMS TO EVALUATE THE EFFECT OF TUMOR SIZE AND CENTRAL LOCATION IN SHORT-TERM SAFETY AND EFFICACY OF PERCUTANEOUS CEUS- AND CT-GUIDED MWA IN BIOPSY-PROVEN RCC TUMORS.FROM JANUARY 2013 TO MARCH 2017, 56 CONSECUTIVE PATIENTS (44 MALES,25 FEMALES) MEDIAN AGE OF 66 YEARS (27¿93) WITH SUSPICIOUS RENAL MASSES,AND WHO UNDERWENT PERCUTANEOUS MWA, WERE INCLUDED IN THIS STUDY. THE TUMOR MICROWAVE ABLATION WAS PERFORMED USING ONE OR TWO COMMERCIALLY AVAILABLE 15-CM, 17-G NEEDLE ANTENNAS (NEUWAVE PR 15; NEUWAVE MEDICAL, MADISON, WIS) MATED TO A 2.45-GHZ MICROWAVE GENERATOR CAPABLE OF 65 W PER ANTENNA (CERTUS; NEUWAVE MEDICAL, MADISON, WIS). FOR EXOPHYTIC LESIONS 2 CM OR LESS, A SINGLE ANTENNA WAS GUIDED TO THE CENTER OF THE LESION, BISECTING IT. FOR ENDOPHYTIC OR LARGER THAN 2-CM LESIONS, TWO ANTENNAS WERE PLACED IN THE OUTER THIRD OF THE LESION TO TRISECT IT.THE MAJORITY OF PATIENTS (67%) HAD A FOLLOW- UP WITHIN 6¿12 MONTHS WHILE 17% (1¿2 YEARS), 10.2% (2¿3 YEARS), AND 5.8% (3¿5 YEARS). REPORTED COMPLICATION INCLUDED: SECONDARY TECHNICAL SUCCESS, LESIONS REQUIRED SECOND ABLATION. AFTER THE SECOND ABLATION THE COMPLETE NECROSIS WAS ACHIEVED WITHOUT INCREASING THE RATES OF COMPLICATION OR TUMOR RECURRENCE(N=5). LOCAL TUMOR PROGRESSION (N=4). THE OVERALL COMPLICATION WAS ENTIRELY COMPRISED OF GRADE I AND II EVENTS SUCH AS A SELF-LIMITED RETROPERITONEAL HEMATOMA AND POST-PROCEDURAL PAIN REQUIRING NARCOTICS (N=3). IT WAS CONCLUDED, THAT THE STUDY COHORT SHOWED THAT CEUS AND CT-GUIDED MWA IS A SAFE AND EFFECTIVE TREATMENT FOR RCCS REGARDLESS OF TUMOR LOCATION AND NEPHROMETRY SCORE WITH A HIGH RATE OF TECHNICAL SUCCESS, LOW COMPLICATION AND LOCAL TUMOR PROGRESSION RATES WITHIN A SHORT-TERM FOLLOW-UP PERIOD.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1043849 NEUWAVE PR PROBE 15CM 17GA SYSTEM, ABLATION, MICROWAVE AND ACCESSORIES NEY NEUWAVE MEDICAL, INC. PR15 00853719006395

    Patients

    Seq Age Sex Outcome Treatment
    1